tbuckley/cabot-search huggingface dataset:
Reply
Authors: Margarita Papatheodoridi, Anna S. Lok, George V. Papatheodoridis
Journal: Hepatology (2022)

M. Papatheodoridi: none; A.S. Lok: research grants from Bristol-Myers Squibb, Gilead, and TARGET; G.V. Papatheodoiridis: advisor/lecturer for Amgen, Gilead, GlaxoSmithKline, Ipsen, Janssen, Novo Nordisk, Roche, and Takeda and research grants from Gilead.
Corrigendum to Zhang J, Cai J, Cui Y, Jiang S, Wei J, Kim YC, Chan J, Thalakola A, Le T, Xu L, Wang L, Jiang K, Wang X, Wang H, Cheng F, Buggs J, Koepsell H, Vallon V, Liu R. “Role of the macula densa sodium glucose cotransporter type 1-neuronal nitric oxide synthase-tubuloglomerular feedback pathway in diabetic hyperfiltration.” Kidney Int. 2022;101:541–550
Authors: Jie Zhang, Jing Cai, Yu Cui, Shan Jiang, Jin Wei, Young Chul Kim, Jenna Chan, Anish Thalakola, Thanh Le, Lan Xu, Lei Wang, Kun Jiang, Ximing Wang, Haibo Wang, Feng Cheng, Jacentha Buggs, Hermann Koepsell, Volker Vallon, Ruisheng Liu
Journal: Kidney International (2022)
The first reactive vaccination campaign against hepatitis E
Authors: Iza Ciglenecki, John Rumunu, Joseph F Wamala, Patrick Nkemenang, Jetske Duncker, Robin Nesbitt, Etienne Gignoux, Trish Newport, Melat Heile, Christine Jamet, Monica Rull, Andrew S Azman
Journal: The Lancet Infectious Diseases (2022)
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
Authors: Javier Cortes, Hope S. Rugo, David W. Cescon, Seock-Ah Im, Mastura M. Yusof, Carlos Gallardo, Oleg Lipatov, Carlos H. Barrios, Jose Perez-Garcia, Hiroji Iwata, Norikazu Masuda, Marco Torregroza Otero, Erhan Gokmen, Sherene Loi, Zifang Guo, Xuan Zhou, Vassiliki Karantza, Wilbur Pan, Peter Schmid
Journal: New England Journal of Medicine (2022)

In an interim analysis of this phase 3 trial, the addition of pembrolizumab to chemotherapy resulted in longer progression-free survival than chemotherapy alone among patients with advanced triple-negative breast cancer whose tumors expressed programmed death ligand 1 (PD-L1) with a combined positive score (CPS; the number of PD-L1–staining tumor cells, lymphocytes, and macrophages, divided by the total number of viable tumor cells, multiplied by 100) of 10 or more. The results of the final analysis of overall survival have not been reported.
Pembrolizumab in the Treatment of Breast Cancer
Authors: Xavier Pivot
Journal: New England Journal of Medicine (2022)

Treatment for triple-negative breast cancers has always been perceived as a "north face" (an allusion to the fact that the north face of a mountain in the northern hemisphere is usually the most formidable and challenging for mountain climbers), and numerous studies have failed to confirm that particular treatments confer a substantial benefit. In this issue of the Journal, Cortes et al.1 report that pembrolizumab — a breakthrough therapeutic treatment for patients with advanced triple-negative breast cancer — combined with chemotherapy prolonged overall survival among these patients. These results confirm the relationship between programmed death ligand 1 (PD-L1) expression and . . .
Case 22-2022: A 34-Year-Old Woman with Cavitary Lung Lesions
Authors: Daniel Restrepo, Adina Haramati, Suzanne M. McCluskey, John A. Branda
Journal: New England Journal of Medicine (2022)

A 34-year-old woman presented with hypercortisolism resulting from a metastatic pancreatic neuroendocrine tumor. Chest CT revealed patchy consolidation with cavitation and tree-in-bud opacities. Management decisions were made.
Phase 1–2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B
Authors: Pratima Chowdary, Susan Shapiro, Mike Makris, Gillian Evans, Sara Boyce, Kate Talks, Gerard Dolan, Ulrike Reiss, Mark Phillips, Anne Riddell, Maria R. Peralta, Michelle Quaye, David W. Patch, Edward Tuddenham, Allison Dane, Marie Watissée, Alison Long, Amit Nathwani
Journal: New England Journal of Medicine (2022)

FLT180a (verbrinacogene setparvovec) is a liver-directed adeno-associated virus (AAV) gene therapy that uses a synthetic capsid and a gain-of-function protein to normalize factor IX levels in patients with hemophilia B.
Development and Validation of Prediction Models of Adverse Kidney Outcomes in the Population With and Without Diabetes
Authors: Morgan E. Grams, Nigel J. Brunskill, Shoshana H. Ballew, Yingying Sang, Josef Coresh, Kunihiro Matsushita, Aditya Surapaneni, Samira Bell, Juan J. Carrero, Gabriel Chodick, Marie Evans, Hiddo J.L. Heerspink, Lesley A. Inker, Kunitoshi Iseki, Philip A. Kalra, H. Lester Kirchner, Brian J. Lee, Adeera Levin, Rupert W. Major, James Medcalf, Girish N. Nadkarni, David M.J. Naimark, Ana C. Ricardo, Simon Sawhney, Manish M. Sood, Natalie Staplin, Nikita Stempniewicz, Benedicte Stengel, Keiichi Sumida, Jamie P. Traynor, Jan van den Brand, Chi-Pang Wen, Mark Woodward, Jae Won Yang, Angela Yee-Moon Wang, Navdeep Tangri
Journal: Diabetes Care (2022)

OBJECTIVE To predict adverse kidney outcomes for use in optimizing medical management and clinical trial design. RESEARCH DESIGN AND METHODS In this meta-analysis of individual participant data, 43 cohorts (N = 1,621,817) from research studies, electronic medical records, and clinical trials with global representation were separated into development and validation cohorts. Models were developed and validated within strata of diabetes mellitus (presence or absence) and estimated glomerular filtration rate (eGFR; ≥60 or &amp;lt;60 mL/min/1.73 m2) to predict a composite of ≥40% decline in eGFR or kidney failure (i.e., receipt of kidney replacement therapy) over 2–3 years. RESULTS There were 17,399 and 24,591 events in development and validation cohorts, respectively. Models predicting ≥40% eGFR decline or kidney failure incorporated age, sex, eGFR, albuminuria, systolic blood pressure, antihypertensive medication use, history of heart failure, coronary heart disease, atrial fibrillation, smoking status, and BMI, and, in those with diabetes, hemoglobin A1c, insulin use, and oral diabetes medication use. The median C-statistic was 0.774 (interquartile range [IQR] = 0.753, 0.782) in the diabetes and higher-eGFR validation cohorts; 0.769 (IQR = 0.758, 0.808) in the diabetes and lower-eGFR validation cohorts; 0.740 (IQR = 0.717, 0.763) in the no diabetes and higher-eGFR validation cohorts; and 0.750 (IQR = 0.731, 0.785) in the no diabetes and lower-eGFR validation cohorts. Incorporating the previous 2-year eGFR slope minimally improved model performance, and then only in the higher-eGFR cohorts. CONCLUSIONS Novel prediction equations for a decline of ≥40% in eGFR can be applied successfully for use in the general population in persons with and without diabetes with higher or lower eGFR.
Seven days in medicine: 13-19 July
Journal: BMJ (2022)

Covid-19 BMA calls for long term plan to keep cases lowThe BMA urged the UK government to develop a long term plan to keep covid cases at low levels after the latest Office for National Statistics survey showed that an estimated one in 19 people in England, one in 17 in Wales and Northern Ireland, and one in 16 in Scotland tested positive in the week to 6 July. 1 Philip Banfield, BMA council chair, said, "There must be recognition from the government that heightened waves of infection lead to greater staff illness and absences, stretching health and care settings to the limit and beyond." Over 50s to get autumn vaccine boosterThe UK government accepted the advice of the Joint Committee on Vaccination and Immunisation to offer an autumn covid booster to over 50s, care home staff and residents, frontline health and care workers, unpaid carers, people in clinical risk groups aged 5-49 years, and household contacts of immunosuppressed people.Those eligible for a flu vaccine will also be expanded to everyone aged 50 or over, primary school children and secondary school pupils in years 7-9, as well as people in clinical risk groups, unpaid carers, and household contacts of immunosuppressed people.
Navigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons
Authors: Paolo Tarantino, Giuseppe Curigliano, Sara M. Tolaney
Journal: Cancer Discovery (2022)

Summary: The confirmation of the HER2-low paradigm is expected to have a major impact in breast oncology. About half of all breast cancers harbor HER2-low expression, which can be targeted with the anti-HER2 antibody–drug conjugate trastuzumab deruxtecan (T-DXd), leading to a relevant survival benefit in the metastatic setting. Given this observation, treatment algorithms for both hormone receptor–positive and triple-negative breast cancer are expected to significantly evolve in the next future. Several challenges, however, remain in the interpretation of HER2-low expression related to its biological role, its pathologic diagnosis, and the definition itself of HER2-low. In this article, we recapitulate the current knowledge on HER2-low breast cancer, discussing whether it should be considered a distinct subtype, how it should be implemented in the clinic, and how its definition may evolve in the coming years with the evolution of our clinical and translational knowledge.
More Than Skin Deep—Understanding the Lived Experience of Acne
Authors: John S. Barbieri, Frances K. Barg
Journal: JAMA Dermatology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Liposomal Bupivacaine—A Boon for Opioid-Sparing Surgery?
Authors: Lucy Luo, Anna Kinio
Journal: JAMA Surgery (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
NT-proBNP in Early Pregnancy and Future Hypertension—More Explorations Needed—Reply
Authors: Alisse Hauspurg, Derek Marsh, Janet Catov
Journal: JAMA Cardiology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Left Ventricular Volume and Outcomes in Patients With Chronic Aortic Regurgitation
Authors: Robert O. Bonow, Patrick T. O’Gara
Journal: JAMA Cardiology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Cell–Cell Interactions Drive Metastasis of Circulating Tumor Microemboli
Authors: Jianxin Tao, Lei Zhu, Mina Yakoub, Christoph Reißfelder, Sonja Loges, Sebastian Schölch
Journal: Cancer Research (2022)

Abstract Circulating tumor cells are the cellular mediators of distant metastasis in solid malignancies. Their metastatic potential can be augmented by clustering with other tumor cells or nonmalignant cells, forming circulating tumor microemboli (CTM). Cell–cell interactions are key regulators within CTM that convey enhanced metastatic properties, including improved cell survival, immune evasion, and effective extravasation into distant organs. However, the cellular and molecular mechanism of CTM formation, as well as the biology of interactions between tumor cells and immune cells, platelets, and stromal cells in the circulation, remains to be determined. Here, we review the current literature on cell–cell interactions in homotypic and heterotypic CTM and provide perspectives on therapeutic strategies to attenuate CTM-mediated metastasis by targeting cell–cell interactions.
Law Enforcement in the Emergency Department
Authors: Rucha Alur, Erin Hall, Utsha Khatri, Sara Jacoby, Eugenia South, Elinore J. Kaufman
Journal: JAMA Surgery (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Liver Transplant Outcomes After Downstaging to Within Milan Criteria—Balancing Patient Benefit With Resource Allocation
Authors: Yuman Fong
Journal: JAMA Surgery (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Cerebrovascular Disease and Sleep-Disordered Breathing Need to Be Accounted for in Cognitive Impairment Following COVID-19—Reply
Authors: Vardan Nersesjan, Daniel Kondziella, Michael E. Benros
Journal: JAMA Psychiatry (2022)

Cerebrovascular Disease and Sleep-Disordered Breathing Need to Be Accounted for in Cognitive Impairment Following COVID-19
Development and Validation of a Model for Opioid Prescribing Following Gynecological Surgery
Authors: Isabel V. Rodriguez, Paige McKeithan Cisa, Karen Monuszko, Julia Salinaro, Ashraf S. Habib, J. Eric Jelovsek, Laura J. Havrilesky, Brittany Davidson
Journal: JAMA Network Open (2022)

<h3>Importance</h3> Overprescription of opioid medications following surgery is well documented. Current prescribing models have been proposed in narrow patient populations, which limits their generalizability. <h3>Objective</h3> To develop and validate a model for predicting outpatient opioid use following a range of gynecological surgical procedures. <h3>Design, Setting, and Participants</h3> In this prognostic study, statistical models were explored using data from a training cohort of participants undergoing gynecological surgery for benign and malignant indications enrolled prospectively at a single institution's academic gynecologic oncology practice from February 2018 to March 2019 (cohort 1) and considering 39 candidate predictors of opioid use. Final models were internally validated using a separate testing cohort enrolled from May 2019 to February 2020 (cohort 2). The best final model was updated by combining cohorts, and an online calculator was created. Data analysis was performed from March to May 2020. <h3>Exposures</h3> Participants completed a preoperative survey and weekly postoperative assessments (up to 6 weeks) following gynecological surgery. Pain management was at the discretion of clinical practitioners. <h3>Main Outcomes and Measures</h3> The response variable used in model development was number of pills used postoperatively, and the primary outcome was model performance using ordinal concordance and Brier score. <h3>Results</h3> Data from 382 female adult participants (mean age, 56 years; range, 18-87 years) undergoing gynecological surgery (minimally invasive procedures, 158 patients [73%] in cohort 1 and 118 patients [71%] in cohort 2; open surgical procedures, 58 patients [27%] in cohort 1 and 48 patients [29%] in cohort 2) were included in model development. One hundred forty-seven patients (38%) used 0 pills after hospital discharge, and the mean (SD) number of pills used was 7 (10) (median [IQR], 3 [0-10] pills). The model used 7 predictors: age, educational attainment, smoking history, anticipated pain medication use, anxiety regarding surgery, operative time, and preoperative pregabalin administration. The ordinal concordance was 0.65 (95% CI, 0.62-0.68) for predicting 5 or more pills (Brier score, 0.22), 0.65 (95% CI, 0.62-0.68) for predicting 10 or more pills (Brier score, 0.18), and 0.65 (95% CI, 0.62-0.68) for predicting 15 or more pills (Brier score, 0.14). <h3>Conclusions and Relevance</h3> This model provides individualized estimates of outpatient opioid use following a range of gynecological surgical procedures for benign and malignant indications with all model inputs available at the time of procedure closing. Implementation of this model into the clinical setting is currently ongoing, with plans for additional validation in other surgical populations.